DOV KADMON to Mice, Inbred C57BL
This is a "connection" page, showing publications DOV KADMON has written about Mice, Inbred C57BL.
Connection Strength
0.060
-
Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8.
Score: 0.022
-
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
Score: 0.006
-
In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6.
Score: 0.006
-
Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60.
Score: 0.004
-
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45.
Score: 0.003
-
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5.
Score: 0.003
-
Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71.
Score: 0.003
-
Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 1993; 7(3):165-79.
Score: 0.003
-
Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):79-85.
Score: 0.003
-
Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
Score: 0.003
-
Experimental oncogene induced prostate cancer. Cancer Surv. 1991; 11:55-71.
Score: 0.003